CD112 Antibody, anti-human, REAfinity™
Synonyms: PRR2, HveB, Nectin-2, PVRL2, NECTIN2
RECOMBINANT EXTENDED VALIDATION
Bioz Star94/100 Bioz rating
7 Citations3 Images
Clone:
REA1195 | R2.525
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD112 Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
Biotin
PE
PE-Vio 615
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-122-771, 130-122-783
Description:
K-562 cells were stained with CD112 antibodies or with the corresponding REA Control (S) antibodies (left peak). Flow cytometry was performed with the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application image
Extended validation for CD112 Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA1195
R2.477
low
R2.525
high
TX31
low
R2.525.2
high

Cells were incubated with an excess of purified unconjugated CD112 (REA1195) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Knockout validation

To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.

Extended-Validation detailed information image

Overlay histogram showing flow cytometric analysis of CD112 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD112-PE (REA1195). Flow cytometry was performed with the MACSQuant Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence

Sensitivity
Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD112 (REA1195). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD112 Antibody, anti-human, REAfinity™
Overview

Clone REA1195 recognizes the human CD112 antigen, a Single-pass type I membrane protein which is also known as Nectin-2, Herpesvirus entry mediator B (HveB) or Poliovirus receptor-related protein 2 (PRR2). Nectins are Ca2+-independent cell adhesion molecules that consist of 4 members: CD111 (Nectin-1), CD112 (Nectin-2), CD113 (Nectin-3), and Nectin-4. CD112 is one of the plasma membrane components of adherens junctions and is widely expressed in human tissues, including hematopoietic cells. It is also over-expressed in various cancers, e.g. breast and ovarian cancers. It has been reported to regulate cell adhesion between epithelial cells through the formation of trans-dimers between adjacent cells. CD112-mediated cell adhesion induces the formation of E-cadherin-based adherens junctions followed by the formation of claudin-based tight junctions. In addition to its function as a cell adhesion molecule, previous studies have suggested that CD112 acts as an organizer of Sertoli cell-spermatid junctions in the testis and of synapse formation by neurons and as an entry receptor for viruses. CD112 is also known to be one of the ligands of CD226 (DNAM-1) and TIGIT.

Additional information: Clone REA1195 displays negligible binding to Fc receptors.

Alternative names

PRR2, HveB, Nectin-2, PVRL2, NECTIN2

Detailed product information

Technical specifications

Clone
REA1195
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD112
Molecular mass of antigen [kDa]
55
Distribution of antigen
endothelial cells, leukocytes, epithelial cells, testicle
Entrez Gene ID
RRID
AB_2819429, AB_2819431, AB_2819427, AB_2819430, AB_2819425, AB_2819424, AB_2819428, AB_2819426

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD112 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support